DMD Digital Health Connections Group Inc

Aptose Biosciences Inc. is a clinical-stage biotechnology company that discovers and develops precision medicines for unmet medical needs in oncology, primarily in the United States. Its clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed a Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and higher-risk myelodysplastic syndromes. The company has license agreements with the National Cancer Institute for the clinical development of tuspetinib, and with Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib. Formerly known as Lorus Therapeutics Inc., it changed its name to Aptose Biosciences Inc. in August 2014, was incorporated in 1986, and is headquartered in Toronto, Canada.